Vesugen is a tripeptide bioregulator targeting vascular endothelial cells — the single cell layer lining every blood vessel in the body, from the largest arteries to the smallest capillaries. Developed by Dr. Vladimir Khavinson at the St. Petersburg Institute of Bioregulation and Gerontology, Vesugen activates gene expression in endothelial cells that is progressively silenced by the cumulative effects of aging, oxidative stress, inflammatory signaling, and metabolic burden — the epigenetic foundation of vascular aging and its cardiovascular consequences.

The vascular endothelium is not merely a passive structural barrier — it is the largest endocrine and paracrine organ in the body by total surface area, producing a remarkable array of signaling molecules that regulate vascular tone (nitric oxide, endothelin), prevent thrombosis (prostacyclin, t-PA, thrombomodulin), control inflammation (ICAM-1, VCAM-1, selectins), and maintain barrier integrity (VE-cadherin, tight junction proteins). Endothelial dysfunction — the impaired ability of endothelial cells to perform these functions — is recognized as the earliest measurable pathological change in atherosclerosis and is strongly predictive of future cardiovascular events.

Vascular aging manifests as progressive endothelial dysfunction: reduced nitric oxide bioavailability (leading to impaired vasodilation, hypertension, and reduced blood flow to target organs), increased endothelial permeability (facilitating lipoprotein infiltration into vessel walls), pro-inflammatory endothelial activation (upregulation of adhesion molecules enabling monocyte adhesion and foam cell formation), and reduced endothelial repair capacity. These changes are driven partly by epigenetic mechanisms — age-related methylation and histone modification progressively silences eNOS (endothelial nitric oxide synthase), KLF2 (a mechanosensitive protective transcription factor), and other endothelial cytoprotective genes.

Vesugen penetrates endothelial cell nuclei and reactivates these silenced vascular protective genes. Target gene expression programs include: eNOS for nitric oxide production, KLF2 and KLF4 for endothelial quiescence and atheroprotection, VE-cadherin and tight junction proteins for barrier maintenance, anti-thrombotic factors, and anti-inflammatory mediators that prevent endothelial activation. This comprehensive endothelial gene expression restoration addresses vascular aging at multiple functional levels simultaneously.

Khavinson group research demonstrates Vesugen effects in aging animal vascular tissue and human clinical contexts. In experimental models, Vesugen treatment improved endothelial-dependent vasodilation (a standard measure of endothelial nitric oxide function), reduced endothelial permeability markers, and improved vascular histological architecture. Human clinical outcomes include improvements in microcirculation parameters, blood flow measurements, and cardiovascular risk marker profiles. The peptide is particularly relevant for aging populations with documented endothelial dysfunction, early atherosclerotic changes, microcirculatory compromise (peripheral circulation, cognitive blood flow), and those with metabolic risk factors for cardiovascular disease.

Protocol: 2mg/day for 10 consecutive days, subcutaneous injection, 2–4 times per year. Combines synergistically with Cardiogen (cardiac tissue bioregulator) for comprehensive cardiovascular epigenetic protection — endothelium + cardiomyocytes addressed together.